Bristol Myers Squibb: ADEPT-2 Study Continues for Alzheimer's Psychosis Treatment

Bristol Myers Squibb announces the continuation of the ADEPT-2 Phase 3 study for psychosis associated with Alzheimer’s Disease. The study aims to evaluate the safety and efficacy of Cobenfy, a potential treatment for hallucinations and delusions in Alzheimer’s patients. After a review, the Data Monitoring Committee recommended enrolling more patients to ensure rigorous standards. BMS remains committed to finding innovative treatments for this unmet medical need.
The ADEPT-2 study focuses on the Neuropsychiatric Inventory-Clinician (NPI-C) and Clinical Global Impression-Severity (CGI-S) as primary endpoints. BMS, a global biopharmaceutical company, is dedicated to developing novel approaches to treat Alzheimer’s Disease and its symptoms.
BristolMyersSquibb #ADEPT2 #AlzheimersResearch #Cobenfy #PsychosisTreatment

source

Jenna Ortega Shares Her...

FDA approves first blood...

Norah O'Donnell's Melanoma Diagnosis:...

Into the Fog: Living...

Bristol Myers Squibb: ADEPT-2 Study Continues for Alzheimer’s Psychosis Treatment

Jenna Ortega Shares Her Lifelong Struggle With OCD

FDA approves first blood test to help screen for Alzheimer’s disease

Norah O'Donnell's Melanoma Diagnosis: Why Early Detection Matters

Into the Fog: Living with Early-Onset Alzheimer’s | WebMD

Jenna Ortega Shares Her Lifelong Struggle With OCD

Jenna Ortega Shares Her Lifelong Struggle With OCD

FDA approves first blood test to help screen for Alzheimer’s disease

Norah O'Donnell's Melanoma Diagnosis: Why Early Detection Matters

Into the Fog: Living with Early-Onset Alzheimer’s | WebMD

Jenna Ortega Shares Her Lifelong Struggle With OCD

FDA approves first blood test to help screen for Alzheimer’s disease

Norah O'Donnell's Melanoma Diagnosis: Why Early Detection Matters